No Data
Tianjin Ringpu Bio-Technology (300119.SZ): has laid out multiple products in the mRNA vaccine pipeline.
Gelonghui reported on February 26th that Tianjin Ringpu Bio-Technology (300119.SZ) stated on the investor interaction platform that the company has laid out multiple products in the mRNA vaccine pipeline, such as in areas related to livestock, pets, and ruminant animal health products. There may be uncertainties regarding the research and development, approval, industrialization, and commercialization of veterinary drug products; please be aware of the associated risks.
The Three-year Loss for Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Shareholders Likely Driven by Its Shrinking Earnings
Tianjin Ringpu Bio-Technology (300119.SZ): This year, new products such as cat interferon and oral deworming medicines are planned to be launched in the pet sector.
On February 14th, Gelonghui reported that Tianjin Ringpu Bio-Technology (300119.SZ) stated on the investor interaction platform that Chao Bixin plans to launch sales in the first quarter, and in the pet sector, plans to launch new products this year including cat interferon, oral deworming medications, hair removal paste, and probiotics.
Tianjin Ringpu Bio-Technology (300119.SZ) has repurchased a cumulative 1.3748% of its shares at a cost of approximately 0.12 billion yuan.
Tianjin Ringpu Bio-Technology (300119.SZ) has announced that as of January 31, 2025, the company will carry out centralized bidding...
Little Excitement Around Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Earnings
Zheshang: Xiaohongshu is welcoming overseas traffic, and pet brands are expected to seize the opportunities for going abroad.
Leveraging the inherent "grass-planting gene" advantage of Xiaohongshu, the pet Industry is expected to seize the business opportunities arising from the new trend.
Earnings Working Against Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Share Price